Drug Profile
Research programme: Alzheimer's disease therapeutics - B&C Pharma
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator B&C Pharma
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Alzheimer's-disease in South Korea
- 06 Jul 2016 Early research in Alzheimer's disease in South Korea (unspecified route)